T3 Pharma research project receives support by the Gebert Rüf Stiftung

The Gebert Rüf Stiftung has announced the winners of the call 2016 «Microbials – Direct Use of Micro-Organisms». Amongst the supported projects is T3 Pharma’s innovative bacteria-based cancer therapy. The applied research project takes place at the University of Basel, the results will allow T3 Pharma to expand its activities in the field of cancer treatment using live bacteria.

With the call «Microbials – Direct Use of Micro-Organisms», held for the first time, the Gebert Rüf Stiftung seeks to jumpstart the direct use of modified or domesticated micro-organisms in human and veterinary medicine as well as other areas. Out of 54 submissions 5 projects were selected for funding. «Microbial Treatment of Solid Tumors», a collaborative effort between the Biozentrum and the Department Biomedicine of the University of Basel and T3 Pharma, is amongst the selected projects and will receive CHF 400’000 in the next two years.

“Our bacteria-based therapies hold great potential for the treatment of solid tumors and it is our aim to broadly exploit this innovative platform”, said Dr. Simon Ittig, CEO of T3 Pharma. “We are very pleased that the Gebert Rüf Stiftung shares this vision and are convinced that its support will help to significantly advance the project.”